News
New publication: Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project
20 Dec 2018
ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer’s disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
You can read the full publication here: https://doi.org/10.3233/JAD-180370
More News
New publication: Health economic modeling for Alzheimer's disease: Expert perspectives
16 Nov 2022
The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers....
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
09 May 2022
Madrid, 9 May 2022 – Today, the members of the
Big Data 4 Better Outcomes: Recommendations for the European Health Data Space
16 Jul 2021
In light of our experience in various projects of the Innovative Medicines Initiative’s Big Data 4...
New publication: Conducting public involvement in dementia research: The contribution of the European Working Group of People with Dementia to the ROADMAP project
06 Apr 2021
Dementia outcomes include memory loss, language impairment, reduced quality of life and personality changes. Research suggests that outcomes selected for dementia clinical trials might not be the most important to people affected....